Quick Facts

• May be used in the management of respiratory tract infections.
• Provides assistance in addressing certain skin and soft tissue infections.
• Used in combination with other therapeutic agents for the management of duodenal ulcers caused by specific bacteria.
• Can be an option for treating infections caused by Mycobacterium avium complex (MAC).

---

Tuclarit may be used for the management of infections caused by susceptible microorganisms. These include respiratory tract infections, such as pneumonia and bronchitis, as well as infections of the sinuses and throat. The medication also provides assistance in addressing certain mild-to-moderate infections of the skin and soft tissues, including folliculitis and cellulitis.

Furthermore, Tuclarit can be an option for treating or preventing disseminated infections related to the Mycobacterium avium complex (MAC). It is also part of a regimen used to address duodenal ulcers in combination with other medicines when the ulcer is caused by Helicobacter pylori bacteria. It is essential to adhere to the therapeutic strategy determined by a healthcare provider.

Regulatory References

1. NIH MedlinePlus guidance on Clarithromycin

The eligibility for using this medicine, which is based on official government regulatory documents for Clarithromycin, is strictly defined by contraindications (absolute exclusions) and specific population restrictions.

Populations Who Must Not Use This Medicine (Contraindicated):

• Individuals with a known hypersensitivity or allergic reaction to clarithromycin, erythromycin, or any macrolide antibacterial drug.
• Patients with a history of cholestatic jaundice or hepatic dysfunction specifically associated with prior clarithromycin use.
• Individuals with pre-existing heart rhythm conditions, including documented QT prolongation (congenital or acquired) or ventricular cardiac arrhythmia (such as torsades de pointes).
• Those with severe hepatic failure combined with renal impairment.
• Individuals concurrently taking a list of specific medications, including certain HMG-CoA reductase inhibitors (statins), cisapride, pimozide, ergot alkaloids, lurasidone, and colchicine (in patients with renal or hepatic impairment).

Age and Condition-Specific Considerations:

Population Group	Eligibility Status (Regulatory Basis)
Infants (under 6 months)	Use Not Established for safety and efficacy in all indications.
Children (under 12 years)	Tablets are not recommended; Paediatric Suspension is the appropriate formulation.
Severe Renal Impairment (CrCl < 30 mL/min)	Use requires dosage reduction (typically by half).
Pregnancy/Lactation	May cause fetal harm (animal data); consider discontinuing nursing during treatment.

Interactions with Other Medicines and Products

Tuclarit’s interaction profile is primarily defined by its documented effect on drug metabolism and clearance. The medicine is classified by regulatory authorities as a strong inhibitor of the CYP3A4 enzyme and a documented inhibitor of the P-glycoprotein (P-gp) drug transporter.

This inhibitory activity can significantly increase the systemic exposure (plasma concentrations) of numerous co-administered medicines that are substrates for these pathways. This increased exposure is the basis for several documented restrictions, including combinations that are formally contraindicated by government regulators.

---

Formally Contraindicated Combinations

Co-administration of Tuclarit is explicitly prohibited with the following medicines due to the high risk of serious adverse reactions, such as cardiac arrhythmias (QT prolongation) or severe toxicity:

• HMG-CoA Reductase Inhibitors (Statins): Lovastatin and Simvastatin.
• Ergot Alkaloids: Ergotamine and Dihydroergotamine (risk of acute toxicity).
• Cardiotoxic Agents: Pimozide, Cisapride, Astemizole, and Terfenadine.
• Other Agents: Lomitapide, Lurasidone, Ticagrelor, Ivabradine, Ranolazine, and oral Midazolam.

---

Other Documented Constraints

Interaction Type	Constraint/Note
Population Constraint	Co-administration with Colchicine is contraindicated in patients with existing renal or hepatic impairment.
Food Requirement	The extended-release tablet formulation must be taken with food to ensure proper drug absorption.
Pharmacodynamic Risk	Co-administration with Warfarin is associated with an increased risk of bleeding, evidenced by elevated International Normalized Ratio (INR).

How Tuclarit Works: Mechanism of Action

Blocking Bacterial Protein Production

Tuclarit exerts its primary action by targeting the bacterial 50S ribosomal subunit. The drug and its active metabolite, 14-hydroxyclarithromycin, bind reversibly to the 23S ribosomal RNA component, a key site within the ribosome. This interaction directly inhibits the peptidyl transferase activity and blocks the translocation step of protein synthesis. This molecular interference halts the assembly of amino acid chains, resulting in the cessation or reduction of bacterial protein synthesis and subsequent inhibition of bacterial proliferation.

Inhibition of Human Metabolism and Transport

Beyond its antibacterial effect, Tuclarit also acts as an inhibitor of the human CYP3A4 enzyme in the liver and the P-glycoprotein (P-gp) efflux pump. This inhibitory action limits the metabolic breakdown and cellular export of certain co-administered medications that are substrates for these proteins, resulting in altered systemic concentrations and half-lives for those compounds.

Administration Routes and Standard Dosing

Tuclarit (Clarithromycin) is administered via the oral route using immediate-release tablets, extended-release tablets, or an oral suspension. It may also be administered as an intravenous infusion in a hospital setting for a short duration, typically transitioning to oral forms.

For most infections, the standard adult regimen for the immediate-release tablet is 250 mg to 500 mg taken twice daily (every 12 hours). The extended-release formulation is typically prescribed as 1000 mg taken once daily. Treatment courses commonly range from 7 to 14 days, though specific regimens, such as those for H. pylori eradication, may dictate a precise 10- or 14-day duration.

Administration Conditions and Adjustments

Proper use depends on the specific dosage form. Immediate-release tablets and the oral suspension can be taken without regard to meals, as food does not significantly affect the extent of the drug's absorption. However, the extended-release tablets must be taken with food. These extended-release forms must be swallowed whole and must not be crushed, chewed, or split, as this alters the drug's release pattern.

For pediatric patients (generally ages 6 months to 12 years), dosing is based on body weight, typically 7.5 mg/kg twice daily, and the oral suspension is the recommended form. Dosage adjustments occur for individuals with severe renal impairment (creatinine clearance < 30 mL/min), where the total daily dosage is typically reduced by half of the maximum recommended dose. If a dose is missed, the standard procedure is to take it immediately unless it is almost time for the next scheduled dose, in which case the missed dose is skipped.

Research evidence / Overview of studies for Tuclarit

---

Evidence for Treating Respiratory Tract Infections

Research examined Tuclarit in short-term Randomized Controlled Trials (RCTs) and multicenter studies to explore its evaluation in people with conditions like pneumonia and bronchitis. These studies primarily focused on two high-level outcomes: the Clinical Resolution, which is the investigator's assessment of how the disease state changes, and Bacteriological Eradication, which is the monitoring of the clearance of the specific bacteria causing the infection. The populations studied included both adults and pediatric patients dealing with common, mild-to-moderate community-acquired respiratory infections.

Studies monitored how symptoms evolved in the observed populations and reported patterns of Clinical Resolution and Bacteriological Eradication assessed over a short-term observation period at the conclusion of treatment. The existing evidence is primarily focused on this immediate period after treatment. Long-term effects are not fully established, meaning the durability of the effect after the initial recovery is not well characterized by the current clinical trial data.

---

Evidence for Combination Therapy in Duodenal Ulcers

Research examined Tuclarit in intermediate-term Randomized Controlled Trials (RCTs) exploring its evaluation as part of a multi-drug regimen for people with Helicobacter pylori infection, which is associated with duodenal ulcers. These studies specifically examined the Microbial Eradication Rate—the assessment of H. pylori bacteria clearance—and the Healing of Ulcer Lesions themselves. The study populations were adults with confirmed infection and associated ulcer disease.

Research describes how microbial eradication was measured, noting that eradication measurements may vary based on the specific combination of medicines used and the geographical location of the trial. Because the drug is only studied as one part of a required multi-drug regimen, the research provides limited insight into the isolated characteristics of Tuclarit itself. Also, the data show patterns related to regional differences in microbial resistance, suggesting that results apply only to the populations studied and may not be predictive of outcomes in areas with high resistance.

---

What is Still Uncertain About Tuclarit Research

The existing evidence landscape has several areas where certainty remains low or where research is ongoing. Evidence quality varies across studies, with some indications supported by a greater volume of high-quality RCTs than others. A major limitation is that comparative evidence is lacking against the most modern standards of care for some indications. Furthermore, while studies monitored short-term changes, there is limited information for long-term outcomes and safety across all populations.

Common questions about Tuclarit (FAQ)

---

Q: How quickly should I expect Tuclarit to start working?

As an antibiotic, Tuclarit begins to act against susceptible bacteria soon after it is taken. Official sources, however, do not provide a specific timeframe for when a patient can expect to feel symptomatic relief. Clinical improvement is generally evaluated over the course of treatment.

Q: Is it normal to feel tired after starting Tuclarit?

Official product information classifies some central nervous system effects, such as insomnia (difficulty sleeping) and headache, as common adverse reactions. While general fatigue or tiredness is not explicitly listed in the common adverse reaction categories, the label does include other related effects.

Q: Does Tuclarit affect birth control effectiveness?

Official documents for macrolide antibiotics, the class Tuclarit belongs to, sometimes suggest that co-administration with certain hormonal contraceptives may require careful monitoring. This is due to potential interaction risks that can affect how the body processes the hormones.

Q: Can people with high blood pressure use Tuclarit?

Official warnings about Tuclarit focus on the need for caution in patients with existing heart conditions such as coronary artery disease and severe cardiac insufficiency. While high blood pressure (hypertension) itself is not explicitly listed as a contraindication in the drug’s labeling, eligibility is dependent on general heart health status.

Q: Are there special considerations for older adults (seniors) taking Tuclarit?

Official warnings emphasize that caution is necessary when older adults use Tuclarit, particularly if they are also taking the medicine colchicine or have kidney problems. Reports indicate a need for caution when co-administered with colchicine in this population.

Q: What kind of screening tests are sometimes done before a person starts Tuclarit?

Since Tuclarit is contraindicated (prohibited) for use in individuals with certain electrolyte imbalances (such as hypokalaemia, or low potassium) and specific heart rhythm conditions (QT prolongation), official documents suggest the importance of assessing for these conditions prior to initiation.

Q: Are there any reported interactions between Tuclarit and herbal supplements?

Official information classifies Tuclarit as an inhibitor of the CYP3A4 enzyme, a pathway that metabolizes many other substances. Although the label may not list specific herbal products, many common supplements (like St. John’s Wort) interact with this same pathway. It is important to know if supplements affect this pathway.

Q: Does Tuclarit have any known effect on mood or anxiety?

The official safety profile includes several neuropsychiatric adverse reactions listed as uncommon or with frequency not known, such as anxiety and confusional states. These effects are based on data reported during clinical use.

Q: Do different strengths of Tuclarit have different side effect profiles?

Official product descriptions list side effects based on the drug's active ingredient regardless of the dosage. However, they indicate that adverse reactions are often dose-related, which means that the intensity or frequency of side effects may vary with the strength of the medicine prescribed.

Q: Does taking Tuclarit require any specific monitoring by a healthcare provider?

Official warnings about the risk of QT prolongation (a change in heart rhythm) and potential for hepatotoxicity (liver damage) suggest that specific medical monitoring may be appropriate during treatment. Such warnings suggest that medical checks of ECG (heart tracing) or liver function may be appropriate.

Q: How long does the effect of a single dose of Tuclarit usually last?

The duration of the therapeutic effect for a single dose is generally reflected in the official dosing schedules. The immediate-release tablet is typically prescribed twice daily to maintain effectiveness, while the extended-release formulation is taken once daily.

Q: Are there any common foods or drinks that should be avoided when taking Tuclarit?

Official warnings classify Tuclarit as interacting with the CYP3A4 enzyme. Substances that inhibit this enzyme, such as grapefruit juice and related citrus juices may increase drug concentration in the body.

Q: What is the difference between Tuclarit and a placebo in clinical trials?

Clinical trial summaries report that subjects receiving Tuclarit achieved a significantly higher rate of clinical resolution (symptom improvement) and bacteriological eradication (clearing the infection) than subjects receiving a non-active treatment (placebo).

Q: Is it possible for Tuclarit to stop working after several months?

Official regulatory documents mention the potential for microbial resistance to macrolide antibiotics, the class Tuclarit belongs to. If the bacteria causing the infection become resistant to the medicine, this could lead to a lack of efficacy against that specific bacterial strain.

Official Storage and Disposal Guidelines

Storing Tuclarit must adhere strictly to regulatory requirements to maintain product integrity. Tablets should be kept at Controlled Room Temperature (20 C to 25 C) and protected from excess heat, moisture, and light. It is mandatory to keep the medicine in its tightly closed, original container and place it out of the sight and reach of children.

For the liquid oral suspension, the reconstituted product must not be refrigerated and any unused portion must be discarded after 14 days.

Disposal of unused or expired Tuclarit should follow official guidance, such as utilizing a drug take-back program. If a take-back option is unavailable, the product must be mixed with an undesirable substance and sealed before being placed in household trash, in accordance with local regulatory rules.